Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.63
- Piotroski Score 3.00
- Grade Buy
- Symbol (ADAP)
- Company Adaptimmune Therapeutics plc
- Price $0.83
- Changes Percentage (0.3%)
- Change -$0
- Day Low $0.79
- Day High $0.83
- Year High $2.05
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $3.00
- High Stock Price Target $4.00
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.73
- Trailing P/E Ratio -1.4
- Forward P/E Ratio -1.4
- P/E Growth -1.4
- Net Income $-114,312,372
Income Statement
Quarterly
Annual
Latest News of ADAP
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
BioNTech SE reported a significant increase in third-quarter revenues to 1.244 billion euros, driven by earlier approvals for its variant-adapted COVID-19 vaccines. The company expects full-year 2024 ...
By Yahoo! Finance | 1 day ago -
Kerri Einarson adapts to constant lineup shuffling on her curling team | Globalnews.ca
Kerri Einarson's curling team faces lineup changes with Joanne Courtney substituting for injured Shannon Birchard. Despite challenges, Einarson's team remains positive and adaptable, focusing on perfo...
By Global News | 5 days ago -
JetBlue founder and low-cost airline veteran explains how struggling airlines need to adapt to survive right now
Budget airlines like Spirit and Frontier are evolving their strategies to survive in a changing market post-pandemic. Industry veteran David Neeleman suggests merging struggling airlines and adopting ...
By Business Insider | 6 days ago
